Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc. (ARMP)
Filing Type: Form 8-K (Current Report)
Date of Report: May 1, 2025
Reporting Period: Event date of May 1, 2025
Business Focus: Development of bacteriophage therapy to treat Staphylococcus aureus bacteremia infections.
Key Financial Metrics
This filing reports a specific funding event rather than comprehensive financial statements.
- New Funding Received: $4.65 million
- Funding Source: U.S. Department of Defense
- Funding Type: Non-dilutive award
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for total revenue, net income, operating cash flow, or margins for the period.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or liquidity ratios.
Material Changes
The primary material change is the receipt of $4.65 million in non-dilutive award funding from the U.S. Department of Defense. This represents a significant cash inflow intended to support the development of the company's bacteriophage therapy pipeline without diluting existing shareholders.
Outlook, Risks, and Management Commentary
Management Commentary: The company announced the funding via a press release (Exhibit 99.1) incorporated by reference. The funds are designated for the development of treatments for Staphylococcus aureus bacteremia infections.
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the standard operational context of a biopharmaceutical development company.
Investor Verification Checklist
- Verify the terms and milestones associated with the $4.65 million Department of Defense award.
- Review the full text of the press release (Exhibit 99.1) for specific details on how the funds will be allocated.
- Confirm the impact of this non-dilutive funding on the company's current cash runway.
- Check subsequent filings for updates on the clinical progress of the Staphylococcus aureus therapy.